Formulation and Evaluation of Latanoprost Ophthalmic Gel for Enhanced Ocular Bioavailability
Keywords:
Latanoprost, Latanoprost, ophthalmic gel, ophthalmic gel, glaucoma, glaucoma, intraocular pressure (IOP), prolonged drug releaseAbstract
One of the main causes of permanent blindness is glaucoma, a chronic eye condition that is mostly linked to high intraocular pressure (IOP). As a prostaglandin F2α analogue, the well-known IOP-lowering drug latanoprost has a limited ocular bioavailability due to its rapid removal from the eye's surface when applied as conventional eye drops. In order to improve precorneal retention time and prolonged medication release, this study aims to create and assess an ocular gel formulation based on latanoprost. The formulation was prepared using Carbopol 940 and HPMC (K15M and E3) as mucoadhesive polymers, propylene glycol for solubility enhancement, and benzalkonium chloride and EDTA as antimicrobial preservatives. Important characteristics such as pH, viscosity, gel strength, osmolality, drug content, and in vitro drug release were assessed for the gel. The medication release profile was evaluated using simulated tear fluid in Franz diffusion cells. Formulations F9 and F10 outperformed the other trial batches in terms of physicochemical properties and achieved 100% release with sustained release over 8 hours. There was no microbiological contamination, according to the sterility test. The outcomes showed that, in comparison to eye drops, the gel formulation offers a more regulated drug delivery profile and successfully extends ocular residence duration. In the treatment of glaucoma, this may result in increased therapeutic effectiveness, decreased dosage frequency, and greater patient compliance.
Downloads
Metrics
References
Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. Jama. 2014; 14;311(18):1901-11. doi:10.1001/jama.2014.3192
Coleman AL, Miglior S. Risk factors for glaucoma onset and progression. Survey of ophthalmology. 2008 Nov 1;53(6):S3-10. https://doi.org/10.1016/j.survophthal.2008.08.006
Doucette LP, Walter MA. Prostaglandins in the eye: Function, expression, and roles in glaucoma. Ophthalmic genetics. 2017; 4;38(2):108-16. https://doi.org/10.3109/13816810.2016.1164193
Jansook P, Loftsson T. Aqueous prostaglandin eye drop formulations. Pharmaceutics. 2022; 9;14(10):2142. https://doi.org/10.3390/pharmaceutics14102142
Farkouh A, Frigo P, Czejka M. Systemic side effects of eye drops: a pharmacokinetic perspective. Clinical ophthalmology. 2016; 7:2433-41. https://doi.org/10.2147/OPTH.S118409
Lanier OL, Manfre MG, Bailey C, Liu Z, Sparks Z, Kulkarni S, Chauhan A. Review of approaches for increasing ophthalmic bioavailability for eye drop formulations. Aaps Pharmscitech. 2021; 22:1-6. 10.1208/s12249-021-01977-0
Gaudana R, Ananthula HK, Parenky A, Mitra AK. Ocular drug delivery. The AAPS journal. 2010; 12:348-60. 10.1208/s12248 010-9183-3
Belamkar A, Harris A, Zukerman R, Siesky B, Oddone F, Verticchio Vercellin A, Ciulla TA. Sustained release glaucoma therapies: Novel modalities for overcoming key treatment barriers associated with topical medications. Annals of Medicine. 2022; 31:54(1):343-58. https://doi.org/10.1080/07853890.2021.1955146
Cassano R, Di Gioia ML, Trombino S. Gel-based materials for ophthalmic drug delivery. Gels. 2021; 29;7(3):130. https://doi.org/10.3390/gels7030130
Nguyen T, Latkany R. Review of hydroxypropyl cellulose ophthalmic inserts for treatment of dry eye. Clinical ophthalmology. 2011; 11:587-91. https://doi.org/10.2147/OPTH.S13889
Bhandwalkar MJ, Inamdar IK, Kalbhare SB, Changan AD, Mandrupkar SN. A review on in situ Nasal Gels for Nasal drug delivery system. Journal of Pharmaceutical Advanced Research. 2020 ;3(12):1062-73.
Merchel Piovesan Pereira B, Tagkopoulos I. Benzalkonium chlorides: uses, regulatory status, and microbial resistance. Applied and environmental microbiology. 2019; 1;85(13): e00377-19. https://doi.org/10.1128/AEM.00377-19
Pandey M, Choudhury H, binti Abd Aziz A, Bhattamisra SK, Gorain B, Su JS, Tan CL, Chin WY, Yip KY. Potential of stimuli-responsive in situ gel system for sustained ocular drug delivery: Recent progress and contemporary research. Polymers. 2021; 20;13(8):1340. https://doi.org/10.3390/polym13081340
Omidian H, Wilson RL. Long-Acting Gel Formulations: Advancing Drug Delivery across Diverse Therapeutic Areas. Pharmaceuticals. 2024; 12;17(4):493. https://doi.org/10.3390/ph17040493
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
Terms:
- Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
